Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call Transcript
Good day, ladies and gentlemen, and welcome to the Madrigal Pharmaceuticals Resmetirom AASLD Clinical Data Review Conference Call. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference, Dr. Paul Friedman, Chairman and Executive Officer of Madrigal. Dr. Friedman, you may begin.
Thanks. Hello, and thanks for joining us on the call today. This is the fine print dealing with forward-looking statements we might make today. Please see our latest SEC filings for a summary of the risk factors associated with our business.
The primary purpose of the call is to review the latest data on resmetirom from the open-label portion of our ongoing Phase III MAESTRO-NAFLD-1 study, which was just presented at AASLD. Dr. Harrison will take us through these data, Dr. Stephen Harrison.
We're also entering an exciting period for Madrigal with the planned releases in the coming months of top line placebo-controlled
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |